Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Susanna Naggie

Infectious Disease Durham, NC Medical Doctor

NPI 1831248855 CMS profile 37453

2100 Erwin Rd, Durham, NC 27710

Open in the dashboard

General payments

$4,118

4 records reported · program years 2019–2024

Research payments

$53,257

Paid to them · 17 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,649,289 paid to institutions, not to them · program years 2019–2021

Through program year 2024, Susanna Naggie of Durham, NC is reported in the CMS Open Payments database as having received $4,118 across 4 general payments and $53,257 in research payments paid to them. Separately, studies naming them as principal investigator received $2,649,289 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 Research $5,411 1
2023 Research $212 1
2022 Research $12,943 5
2021 General $2,540 1
2021 Research $10,185 5
2020 General $1,500 1
2020 Research $24,507 5
2019 General $78 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susanna Naggie
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Susanna Naggie were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Susanna Naggie Infectious Disease median Middle half National median
2019 $78 $190 $60–$862 $163
2020 $1,500 $124 $32–$606 $114
2021 $2,540 $148 $38–$905 $132
2022 $0 $166 $50–$834 $149
2023 $0 $171 $57–$787 $160
2024 $0 $176 $52–$752 $164
2025 $0 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Gilead Sciences, Inc. $2,618 3 payments
  2. Theratechnologies Inc. $1,500 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $2,540 1 payment
  2. Honoraria $1,500 1 payment
  3. Food and Beverage $78 2 payments
Research payments came from Research payments · program years 2019–2024
  1. E.R. Squibb & Sons, L.L.C. $53,257 17 payments

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

172

Median for Infectious Disease: 268

Drug cost

$279,987

Median for Infectious Disease: $217,595

Branded share of claims

47.1%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 39 $162,079
Odefsey Emtricitab/Rilpiviri/Tenof Ala Brand 19 $68,328
Isentress Raltegravir Potassium Brand 12 $25,771
Tivicay Dolutegravir Sodium Brand 11 $22,945
Metoprolol Succinate Generic 11 $256
Atorvastatin Calcium Generic 32 $250
Tamsulosin Hcl Generic 11 $226
Furosemide Generic 11 $69
Amlodipine Besylate Generic 26 $63

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Records

21 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record